D
Donald A. Berry
Researcher at University of Texas MD Anderson Cancer Center
Publications - 449
Citations - 43822
Donald A. Berry is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 85, co-authored 423 publications receiving 38595 citations. Previous affiliations of Donald A. Berry include University of Minnesota & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Effect of screening and adjuvant therapy on mortality from breast cancer
Donald A. Berry,Kathleen A. Cronin,Sylvia K. Plevritis,Dennis G. Fryback,Lauren Clarke,Marvin Zelen,Jeanne S. Mandelblatt,Andrei Yakovlev,J. Dik F. Habbema,Eric J. Feuer +9 more
TL;DR: Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.
Journal ArticleDOI
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron,Donald A. Berry,Constance Cirrincione,Clifford A. Hudis,Eric P. Winer,William J. Gradishar,Nancy E. Davidson,Silvana Martino,Robert B. Livingston,James N. Ingle,Edith A. Perez,John T. Carpenter,David D. Hurd,James F. Holland,Barbara L. Smith,Carolyn I. Sartor,Eleanor H. Leung,Jeffrey S. Abrams,Richard L. Schilsky,Hyman B. Muss,Larry Norton +20 more
TL;DR: Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy.
Journal ArticleDOI
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson,Donald A. Berry,George D. Demetri,Constance Cirrincione,Lori J. Goldstein,Silvana Martino,James N. Ingle,M. Robert Cooper,Daniel F. Hayes,Katherine Tkaczuk,Gini F. Fleming,James F. Holland,David B. Duggan,John T. Carpenter,Emil Frei,Richard L. Schilsky,William C. Wood,Hyman B. Muss,Larry Norton +18 more
TL;DR: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Journal ArticleDOI
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
S. Eva Singletary,Craig Allred,Pandora Ashley,Lawrence W. Bassett,Donald A. Berry,Kirby I. Bland,Patrick I. Borgen,Gary Clark,Stephen B. Edge,Daniel F. Hayes,Lorie L. Hughes,Robert V. P. Hutter,Monica Morrow,David L. Page,Abram Recht,Richard L. Theriault,Ann D. Thor,Donald L. Weaver,H. Samuel Wieand,Frederick L. Greene +19 more
TL;DR: This revised staging system for breast carcinoma will be officially adopted for use in tumor registries in January 2003 and will be useful for the uniform accrual of outcome information in national databases.
Journal ArticleDOI
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more
TL;DR: Overall survival for SABR versus surgery by pooling data from the STARS and ROSEL trials was 95% (95% CI 85-100) in the S ABR group compared with 79% in the surgery group, and recurrence-free survival at 3 years was 86% ( 95% CI 74-100).